Cardiovascular Catch-Up: TAVR Withstands Delta Virus So Far; Stereotaxis Robot Succeeds In Trial
Executive Summary
The impact of the Delta variant of COVID-19 on procedure volumes remains a major concern for transcatheter valve makers, Abbott launches a new PFO closure device, and more highlights from the cardiovascular technology market in early October.
You may also be interested in...
Digital Health Roundup: Digital Therapeutics Push Ahead On Standards, Coverage; FDA’s Software Guidance
In this roundup feature focusing on developments in digital health, we highlight the key news and announcements from October.
Hospital Staffing Shortages Could Impede Recovery Of Procedure Volumes
Even as COVID-19 hospitalization rates are declining, expected staff shortages could force more hospitals to postpone surgeries and interventions in the coming months.
Stereotaxis Continues Its Turnaround, Bringing Robots To Endovascular Intervention
In an interview with Medtech Insight, Stereotaxis CEO David Fischel explained how the company intends to continue its recovery after a troubled near decade of decline.